Peer-influenced content. Sources you trust. No registration required. This is HCN.

JAMA NetworkEffect of Ivermectin vs. Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial

The median time to recovery in a group of 1,800 vaccinated and unvaccinated adults (median age: 48 years) was essentially the same whether the patients received ivermectin or placebo: 12 and 13 days, respectively. Death rate was slightly higher in the ivermectin group and rates of pneumonia and VTE were slightly higher in the placebo group.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form